| INTRODUCTION
Diabetic ketoacidosis (DKA) accounts for 65% of hospitalizations in pediatric patients with type-1 diabetes (T1D) and has a mortality rate between 0.15% and 0.31%. 1 One in 4 children with newonset T1D present in DKA, 2 and children with established T1D
have an 8% annualized risk of developing this complication. This risk increases during adolescence. 3 The management of DKA includes fluid resuscitation and intravenous insulin administration, 4, 5 followed by a transition to subcutaneous insulin. This transition is associated with an increased risk of hypoglycemia and rebound hyperglycemia.
Commonly used intravenous insulin analogs have a half-life of less than 10 minutes. 6 An appropriate overlap of subcutaneous insulin prior to discontinuing the insulin infusion is required to prevent
Abbreviations: BUN, blood urea nitrogen; CHOP, The Children's Hospital of Philadelphia; CSII, continuous subcutaneous insulin infusion; DKA, diabetic ketoacidosis; G+, group receiving glargine ≥ 4 hours before discontinuation of intravenous insulin; G−, group receiving glargine ≤ 2 hours before discontinuation of intravenous insulin; T1D, type 1 diabetes rebound hyperglycemia and ketosis. Guidelines from the American Diabetes Association 7 and the International Society for Pediatric and Adolescent Diabetes 4 recommend subcutaneous insulin between 15 and 120 minutes prior to stopping the infusion. The recommended duration of co-administration depends on the pharmacokinetics of the particular insulin analog used. 4 Multiple daily injection (MDI) regimens include once-or twicedaily administration of long-acting/basal insulin (eg, detemir, glargine) in addition to mealtime administration of fast-acting insulin. The majority of patients treated for DKA receive subcutaneous longacting basal insulin during the transition from intravenous insulin to a home regimen. Glargine and detemir provide a reasonably constant basal insulin action over 24 hours, and are generally dosed once a day, [8] [9] [10] but the long duration of action of these basal analogs can present a challenge when transition from intravenous insulin happens outside of the usual basal dosing schedule. An example of this is where DKA resolves at 5 AM, but family plans to give Lantus each night at 8 PM following discharge. Common approaches used to adjusting the timing of long-acting insulin in the days following transition include: shifting the dose 2 to 4 hours per day to prevent significant insulin "stacking" and risk of hypoglycemia, or giving half of the basal insulin at the time of DKA resolution, followed by the full dose at the next appropriate routine dosing time.
Administering subcutaneous basal insulin at a predetermined time, in addition to receiving intravenous insulin, would facilitate a smooth and flexible transition to a home subcutaneous insulin regimen once DKA had resolved. This would allow all subsequent basal insulin injections to occur on schedule. For these reasons, a protocol that includes early administration of glargine with intravenous insulin has been established at our institution. The aim of this study was to determine if this practice of administering subcutaneous glargine during insulin infusion is associated with an increased risk of hypoglycemia, hypokalemia or other complications in children with DKA. Serial glucose, bicarbonate and potassium measurements were collected for up to 24 hours after insulin infusion discontinuation.
| METHODS

| DKA treatment protocol
At CHOP, the standard management of DKA is consistent with international recommendations. 4 
| Definitions
DKA was defined as pH < 7.3 or bicarbonate < 15 mmol/L, glucose concentration > 200 mg/dL, and detectable urinary or serum ketones. We defined the resolution of acidosis as the time when serum bicarbonate concentration reached 16 mmol/L or higher.
Hypoglycemia was defined as a blood glucose concentration < 60 mg/dL, on laboratory or point of care testing and occurring between the start of insulin infusion until 2 hours after it was stopped. Hypokalemia was defined as serum potassium concentration < 3.5 mmol/L from start of insulin infusion until 24 hours post discontinuation.
| Laboratory measurement
Biochemical tests were performed in the clinical chemistry laboratory at CHOP. Whole blood point of care (POC) Glucose was performed with a Nova meter (Nova Biomedical, Waltham, Massachusetts), which uses a modified glucose-oxidase based amperometric test system with hematocrit and interference correction. Basic Metabolic Panel analytes and HbA1c were performed with a VITROS 5600 Integrated System (Vitros, Raritan, New Jersey). Glucose was measured by glucose-oxidase coupled, colorimetric assay. Sodium was measured by direct potentiometry using methyl monensin as a sodium ionophore. Potassium was measured by direct potentiometry using valinomycin as a potassium ionophore. Bicarbonate was measured by carboxylation reaction coupled with reflectance spectrophotometry.
BUN (BUN) was measured by colorimetric urease reaction. Creatinine was measured by creatine amidinohydrolase oxidation reaction coupled with colorimetric 2-point rate densiometry. HbA1c was measured using spectrophotometry of hemolyzed whole blood, complexed with hexapeptide-glycan immunoglobulin. Urine ketones were measured by bedside sodium nitroprusside colorimetric reaction.
Blood gas analytes including pH and pCO2 were measured using the RAPIDLab 1265 system (Siemens, Erlangen, Germany).
| Statistics
Standard descriptive statistics were used to summarize demographics, initial biochemical measures, time measures, and to determine the proportion of adverse events. All data were described by mean (SD).
Normally distributed data, as determined by Shapiro-Wilk test were compared using Student's t-test. Skewed data were compared using Mann-Whitney U tests (aka rank-sum test). Pearson's χ 2 analysis or Fishers exact test was used to compare proportions. Sub-analysis of hypokalemia within the G+ new-onset patients, and its association with initial potassium level and glargine co-administration time, was done using logistical regression analysis. Statistical significance was defined using a 2-sided P-value <0.05 for all analyses. Statistical analysis was performed using SPSS 22.0 (IBM, New York), Stata 14.1 (StataCorp, L.P., College Station, Texas) and figures were generated existing T1D in the G+ group consisted of 75% using MDI, 8% using 70/30 or NPH, and 17% using CSII ( Table 1 ). The insulin infusion rate (u/kg/h) and total glargine doses (u/kg) were similar between newonset and pre-existing T1D subgroups ( Table 2 ). The duration of DKA and insulin infusion was longer in the G+ group (P = 0.002). Mean Pre-existing T1D (n = 99) New-onset T1D (n = 50) c [Corrected sodium = measured sodium + 0.024 × (Serum glucose − 100)] as defined by Hillier method. 19 duration of hospitalization was unaffected in new-onset (G+: 3.1 days and G−: 3.1 days, P = 0.76) and pre-existing (G+: 1.9 days and G−:
1.7 days, P = 0.73) T1D. Trends in acidosis resolution and glucose concentrations were similar in G+ and G− groups both for children with new-onset and pre-existing T1D (Figure 1 ).
| Hypoglycemia
The mean (SD) minimum glucose concentration during insulin infusion was lower in the G+ than the G− groups, although this did not reach statistical significance (G+: 84 (30) mg/dL, G−: 93 (38) mg/dL, P = 0.24). No patient in either group experienced a severe complication of hypoglycemia such as seizure or loss of consciousness. The incidence of hypoglycemia was similar regardless of glargine coadministration in pre-existing (G+ 29%, G− 20%, P = 0.4) and newonset (G+ 22%, G− 21%, P = 0.9) T1D (Table 2, Figure 2 ). The 1-and 2-hour postinsulin infusion blood glucose trends were similar between groups ( Figure 1A ,B).
| Hypokalemia
The mean initial potassium was 5. 
| Other outcomes
The duration of DKA was 10.9 (G+) vs 6.6 (G−) hours (P = 0.002) in those with pre-existing and 8.1 (G+) vs 5.9 (G−) hours (P = 0.06) in those with new-onset T1D. The rate of DKA resolution was measured by serum bicarbonate, which increased similarly between groups ( Figure 1C, 1D) . Two children included in this study had altered mental status with subsequent CT brain confirmation of cerebral edema. Both of these patients had pre-existing T1D and were in the G− group.
| DISCUSSION
Early administration of glargine in children with DKA prepares the patient for a convenient and expeditious transition to post-discharge long-acting subcutaneous insulin. 12 Thus, the premise of this study was that this may be a preferred method of supporting transition to subcutaneous insulin for children with DKA, provided it is safe. We a Mean (standard deviation) presented unless otherwise stated. P-values calculated using Mann-Whitney U-test unless otherwise specified.
b Hypoglycemia defined as glucose <60 mg/dL.
c Calculated using Pearson χ 2 .
d Calculated using students t-test. 13, 100% T1D). [13] [14] [15] [16] Three studies showed shorter DKA and hospital duration times. 13, 14, 16 One study showed an increase in hypoglycemia and hypokalemia, 13 while no study suggested an increased risk of cerebral edema.
Additional studies have addressed the effect of insulin dose in DKA on hypoglycemia, hypokalemia, resolution of acidosis, and incidence of cerebral edema. A study comparing 1 u/kg/h with 0.1 u/ kg/h intravenous insulin in children with DKA revealed higher rates of hypokalemia (62% vs 18%) and hypoglycemia with higher insulin doses. 17 Another study comparing 0.1 u/kg/h with 0.05 u/kg/h also reported an increased risk of hypokalemia with higher insulin doses (48% vs 20%), but also showed an increased risk of hypoglycemia (20% vs 4%). Higher insulin doses did not result in a faster resolution of DKA. In conclusion, we have shown that the practice of coadministering long-acting subcutaneous insulin and intravenous insulin increases the incidence of hypokalemia. Because there were no clinical complications in our population we believe this practice to be safe and we have found it to facilitate a smooth transition from inpatient to outpatient management. However, if this approach is used, we recommend that clinicians are aware of an associated increased risk of hypokalemia. 
Conflicts of interest
The authors have no conflicts of interest to disclose.
Financial disclosure
The authors have no financial relationships relevant to this article to disclose. 
